---
title: FDA Grants Fast Track Status to Aegle Therapeutics' AGLE-102 for Dystrophic Epidermolysis Bullosa
description: FDA Grants Fast Track Status to Aegle Therapeutics' AGLE-102 for Dystrophic Epidermolysis Bullosa
---

[News ](https://www.yourway.com/news)

# [FDA Grants Fast Track Status to Aegle Therapeutics' AGLE-102 for Dystrophic Epidermolysis Bullosa](https://www.yourway.com/news/fda-grants-fast-track-status-to-aegle-therapeutics-agle-102-for-dystrophic-epidermolysis-bullosa)

 Written by [Yourway](https://www.yourway.com/news/author/yourway) | October 6, 2020

Aegle Therapeutics Corporation [announced](https://www.prnewswire.com/news-releases/fda-grants-fast-track-status-to-aegle-therapeutics-agle-102-for-the-treatment-of-dystrophic-epidermolysis-bullosa-301140426.html) that the FDA has granted Fast Track designation to AGLE-102™ for the treatment of patients with dystrophic epidermolysis bullosa , a rare genetic pediatric skin blistering disorder. AGLE-102 is an extracellular vesicle therapy that delivers proteins, genetic material and regenerative healing factors to diseased and damaged tissue. AGLE-102 will be evaluated in DEB patients in a phase I/IIa trial initiating in 2021. Youway is ready to support customers with Fast Track and other accelerated clinical trials.

[View full post](https://www.yourway.com/news/fda-grants-fast-track-status-to-aegle-therapeutics-agle-102-for-dystrophic-epidermolysis-bullosa)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Yourway"
  },
  "dateModified" : "2020-10-06T09:00:00.544Z",
  "datePublished" : "2020-10-06T09:00:00Z",
  "headline" : "FDA Grants Fast Track Status to Aegle Therapeutics' AGLE-102 for Dystrophic Epidermolysis Bullosa",
  "image" : {
    "@type" : "ImageObject",
    "height" : 2424,
    "url" : "https://f.hubspotusercontent30.net/hubfs/5402331/iStock-1184395006.jpg",
    "width" : 4000
  },
  "mainEntityOfPage" : "https://www.yourway.com/news/fda-grants-fast-track-status-to-aegle-therapeutics-agle-102-for-dystrophic-epidermolysis-bullosa",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "News"
  }
}
```